Core Viewpoint - The article highlights the rising demand for flu vaccines, antiviral medications, and related testing services due to the increasing flu activity across various regions in China as winter approaches [2][6][8]. Group 1: Flu Vaccine and Antiviral Demand - The flu season is expected to drive significant growth in demand for flu vaccines, respiratory testing, and antiviral medications [2][6]. - Recent data indicates a notable increase in flu vaccine appointments and antiviral drug purchases, with some areas reporting over 500% growth in the number of buyers for antiviral medications [7][8]. - Specific antiviral drugs like Marbofloxacin have seen a remarkable increase in demand, with purchases rising over 600% in recent weeks [7]. Group 2: Market Opportunities - Analysts suggest that the current flu outbreak may lead to heightened public and market interest, creating investment opportunities in flu vaccines, virus testing, and cold medications [8]. - The demand for flu-related products is expected to surge, particularly for antiviral medications such as Oseltamivir and Marbofloxacin, as well as traditional Chinese medicine for flu treatment [8]. - The increase in flu cases is likely to boost the need for diagnostic testing, both in hospitals and for home monitoring, indicating a potential market expansion for testing products [8].

Group 1 - The demand for flu-related medications is rising significantly as the flu season approaches, with several stocks in the sector experiencing price surges [1] - Notable stocks that have reached their daily limit include Jindike, Peking University Medicine, and Te Yi Pharmaceutical, among others [1] - Data from Alibaba Health indicates a more than 500% week-on-week increase in the number of people purchasing antiviral flu medications, with Mabalosavir showing a remarkable over 600% increase [1] Group 2 - Experts warn that the H3N2 strain circulating this year is different from previous years, leading to lower immunity in the population and increased transmission risk [2] - The flu virus is known to undergo antigenic drift, but current strains are still within seasonal levels and do not indicate a stronger evolution of the virus [2] Group 3 - Companies are actively ensuring the supply of flu medications and vaccines in response to rising demand [3] - Dongyang Sunshine, a major supplier of Oseltamivir, reports comprehensive coverage of its products across hospitals, pharmacies, and online platforms, maintaining sufficient inventory [3] - Hualan Biological has noted a significant increase in demand for flu vaccines since October, with plans to enhance market supply and ensure timely delivery through cold chain logistics [3]

Core Insights - The flu season has arrived earlier than expected, leading to increased activity in flu-related stocks in the A-share market [1] - Significant sales increases have been reported for antiviral medications, with Oseltamivir sales up 237% and Mabalaosavir up 180% in the past week [1] Stock Performance - Notable stock movements include: - Yipinhong (一品红) up 13% - Hendi Pharmaceutical (亨迪药业) up nearly 11% - Special One Pharmaceutical (特一药业) and Guangji Pharmaceutical (广济药业) both hitting the 10% daily limit up - Other companies like Hainan Haiyao (海南海药) and Peking University Pharmaceutical (北大医药) also saw significant gains [1][2] - The overall market sentiment is positive, with many flu-related stocks experiencing substantial year-to-date increases, such as: - Yipinhong with a year-to-date increase of 225.09% - Hainan Haiyao with a 75.37% increase [2] Consumer Behavior - Data from Alibaba Health indicates a marked increase in the attention and purchase volume of flu medications over the past two weeks, with a more than 500% week-on-week growth in the number of buyers for antiviral drugs [1] - Mabalaosavir has shown exceptional performance, with a 600% increase in the number of buyers compared to the previous period, reflecting heightened consumer awareness regarding flu prevention and treatment [1]

Group 1 - The core viewpoint of the news highlights the strong performance of the Traditional Chinese Medicine (TCM) sector, driven by supportive government policies aimed at innovation and industrial transformation [1][2] - The Shanghai government has issued a document encouraging collaboration among medical institutions, research units, and pharmaceutical companies to create platforms for TCM innovation and industrial transformation [1] - The document supports the development of major TCM varieties and the secondary development of classic varieties, as well as the establishment of mechanisms for collecting and organizing human experience data for drug registration [1] Group 2 - China Galaxy Securities anticipates that policy-driven changes will continue to propel the pharmaceutical industry towards innovation and upgrades, with a focus on finding incremental opportunities in niche markets [2] - The report indicates that domestic innovative drugs are expected to yield results, with several second-generation I/O drugs and ADCs entering phase three clinical trials, which is promising for future developments [2] - The TCM prescription drug market is facing clinical re-evaluation, which may reshape the market landscape and potentially lead to a turning point in TCM gross margins [2] Group 3 - The TCM ETF closely tracks the Zhongzheng TCM Index, which selects listed companies involved in TCM production and sales to reflect the overall performance of TCM concept stocks [2] - As of October 31, 2025, the top ten weighted stocks in the Zhongzheng TCM Index account for 54.92% of the index, including companies like Yunnan Baiyao and Tongrentang [2]

Core Insights - On November 24, a total of 17 companies were investigated by institutions, with 10 companies being surveyed by funds, indicating a strong interest in specific stocks [1] - Among the surveyed companies, 6 attracted more than 5 funds, with Crystal Morning Technology being the most popular, receiving attention from 35 funds [1] - The total market capitalization of the surveyed A-shares includes 1 company with a market cap over 500 billion yuan, and 6 companies with market caps below 100 billion yuan [1] Company Summaries - **Crystal Morning Technology (688099)**: Received the highest interest with 35 funds participating in the survey, latest closing price at 92.72 yuan, and a 5-day price increase of 15.68% [1] - **Weili Transmission (300904)**: Attracted 19 funds, latest closing price at 69.20 yuan, with a 5-day price decrease of 2.40% [1] - **Haiyou New Materials (688680)**: Surveyed by 8 funds, latest closing price at 39.17 yuan, experiencing a significant 5-day price drop of 14.83% [1] - **Sanyuan Bio (301206)**: Engaged 7 funds, latest closing price at 27.32 yuan, with a 5-day decline of 5.07% [1] - **Dayilong (002209)**: Also received attention from 7 funds, latest closing price at 14.39 yuan, with a 5-day decrease of 5.95% [1] - **Yongdong Shares (002753)**: Participated by 5 funds, latest closing price at 8.01 yuan, with a slight increase of 3.35% over 5 days [1] - **Hengyi Petrochemical (000703)**: Surveyed by 3 funds, latest closing price at 6.96 yuan, with a 5-day decline of 7.94% [1] - **Weichai Power (000338)**: Engaged 2 funds, latest closing price at 16.60 yuan, with a 5-day decrease of 6.21% [1] - **Zhongsheng Pharmaceutical (002317)**: Attracted 1 fund, latest closing price at 24.08 yuan, with a 5-day decline of 9.20% [1] - **Meirui New Materials (300848)**: Also surveyed by 1 fund, latest closing price at 14.89 yuan, with a 5-day drop of 10.52% [1]

Core Insights - The demand for influenza medications has surged with the onset of the flu season, particularly for Oseltamivir and Marbofloxacin, indicating a sustained high demand in the coming months [1][3] - Oseltamivir continues to dominate the market, holding over 70% market share, but new entrants like Marbofloxacin are gaining traction [4][8] - The overall influenza activity in China is on the rise, with the H3N2 strain being the predominant virus [2][3] Market Dynamics - Oseltamivir's sales have increased by over 237% recently, while Marbofloxacin's sales rose by 180% [3] - The influenza drug market in China is projected to reach 10.1 billion yuan in 2024 and grow to 11.6 billion yuan by 2030 [3] - The entry of new domestic drugs from companies like Qingfeng Pharmaceutical and Zhongsheng Pharmaceutical signifies a collective rise in China's pharmaceutical industry [7][8] Competitive Landscape - The market is evolving with both old and new drugs; Oseltamivir, despite its long-standing presence, faces challenges from newer medications that offer advantages like single-dose treatment [5][8] - Marbofloxacin was included in the national medical insurance directory shortly after its launch, highlighting its rapid market acceptance [5] - The competition is expected to intensify, focusing on price reductions and market access through insurance negotiations [9] Future Outlook - The flu medication market is likely to see a diversified competitive landscape, with a potential "multi-pillar" structure emerging [8][9] - Factors such as brand reputation, supply chain stability, and the ability to meet seasonal demand will play crucial roles in determining market success [9]

南财智讯11月24日电，众生药业在投资者关系活动中表示，昂拉地韦片是全球首款RNA聚合酶PB2靶点 的甲型流感口服药物，具有快速、强效、低耐药的特点。III期临床试验结果表明，该药物对包括H1和 H3亚型在内的甲型流感病毒株均能显著缩短症状缓解时间，达到主要疗效终点，且安全性良好。钟南 山院士担任该药II期及III期临床研究总负责人，相关研究成果已发表于 《TheLancetRespiratoryMedicine》等国际权威期刊。 ...

| √ | □特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 □业绩说明会 | | 投资者关系活动 类别 | □新闻发布会 □路演活动 | | | □现场参观 □一对一沟通 | | | □其他（ ） | | 参与单位及人员 | 中信建投证券股份有限公司、银华基金管理股份有限公司分 | | | 析师、研究员 | | 时间 | 2025 年 11 月 24 日 14:30～15:30 | | 地点 | 公司会议室 | | 形式 | 现场交流 | | 上市公司 | 1、公司董事会秘书 杨威 | | 接待人员 | 2、公司证券事务代表 陈子敏 1、公司昂拉地韦片有什么特色，是否对 H3N2 毒株有效？ | | | 答：昂拉地韦片是全球首款 RNA 聚合酶 PB2 靶点的甲型 流感口服药物，具有快速、强效、低耐药的特点，能够快速缓 | | | 解全身流感症状、强效抗击流感病毒，兼具低耐药性。 | | | 临床前研究结果表明，对包括奥司他韦耐药株、高致病性 | | 交流内容及具体 | 禽流感病毒株和巴洛沙韦耐药株等在内的多种不同亚型流感 | | 问答记录 | 病毒株具有强大的抑制活性。昂拉 ...

每经AI快讯，有投资者在投资者互动平台提问：公司的创新药减肥药RA1225，为什么能直接进入美国 FDA二期实验？一期不要做吗？ 众生药业（002317.SZ）11月24日在投资者互动平台表示，公司 RAY1225 注射液可在美国开展超重或肥 胖适应症的II期临床试验，系遵循国际和当地新药审评规范的合规推进。公司于2024年12月向美国食品 药品监督管理局（以下简称"FDA"）递交了RAY1225注射液在中国人群的I期和RAY1225注射液治疗中 国肥胖/超重患者与2型糖尿病患者的II期临床研究当时已获得的安全性和有效性数据，申请在美国开展 超重或肥胖患者的II期临床研究，目前FDA已经完成了RAY1225注射液递交资料的安全性审查，同意 RAY1225注射液直接在美国开展超重或肥胖适应症的II期临床试验。 （文章来源：每日经济新闻） ...

Group 1 - The core viewpoint of the news is that Zhongsheng Pharmaceutical experienced a stock price increase of 5.3%, reaching 24.65 CNY per share, with a trading volume of 950 million CNY and a turnover rate of 5.18%, resulting in a total market capitalization of 20.951 billion CNY [1] - Zhongsheng Pharmaceutical, established on December 31, 2001, and listed on December 11, 2009, is primarily engaged in the research, production, and sales of pharmaceuticals. The revenue composition includes 53.03% from traditional Chinese medicine sales, 38.12% from chemical drug sales, 6.13% from Chinese medicinal materials and decoction pieces, 2.14% from raw materials and intermediates, and 0.58% from other sources [1] Group 2 - From the perspective of fund holdings, one fund under Jianxin Fund has a significant position in Zhongsheng Pharmaceutical. Jianxin High-end Medical Stock A (004683) held 403,600 shares in the third quarter, accounting for 5.61% of the fund's net value, making it the fifth-largest holding. The estimated floating profit today is approximately 500,500 CNY [2] - Jianxin High-end Medical Stock A (004683) was established on July 18, 2017, with a current scale of 121 million CNY. Year-to-date returns are 3.98%, ranking 3822 out of 4208 in its category, while the one-year loss is 4.18%, ranking 3823 out of 3981. Since inception, the fund has achieved a return of 42.26% [2]